Stock Analysis

Global Stocks Estimated To Be Undervalued In February 2025

Published

As global markets grapple with geopolitical tensions, fluctuating consumer spending, and tariff uncertainties, investors are keenly observing the shifts in major indices and economic indicators. Amidst these challenges, identifying undervalued stocks becomes crucial as they may offer potential opportunities for growth when broader market sentiment is cautious.

Top 10 Undervalued Stocks Based On Cash Flows

NameCurrent PriceFair Value (Est)Discount (Est)
Chifeng Jilong Gold MiningLtd (SHSE:600988)CN¥18.22CN¥35.9749.3%
Hibino (TSE:2469)¥2852.00¥5631.6749.4%
Sichuan Injet Electric (SZSE:300820)CN¥48.12CN¥94.8149.2%
Power Wind Health Industry (TWSE:8462)NT$112.00NT$223.8850%
Vestas Wind Systems (CPSE:VWS)DKK102.35DKK204.1249.9%
Food & Life Companies (TSE:3563)¥4093.00¥8116.6049.6%
Laboratorio Reig Jofre (BME:RJF)€2.69€5.3249.4%
Cint Group (OM:CINT)SEK6.745SEK13.2949.2%
Better Collective (OM:BETCO)SEK109.20SEK216.5649.6%
Doosan Fuel Cell (KOSE:A336260)₩16510.00₩32744.6349.6%

Click here to see the full list of 498 stocks from our Undervalued Global Stocks Based On Cash Flows screener.

Let's take a closer look at a couple of our picks from the screened companies.

Fomento Económico Mexicano. de (BMV:FEMSA UBD)

Overview: Fomento Económico Mexicano, S.A.B. de C.V., primarily operates as a bottler of Coca-Cola trademark beverages through its subsidiaries and has a market capitalization of MX$598.50 billion.

Operations: FEMSA generates its revenue primarily from its role as a Coca-Cola trademark beverage bottler through its subsidiaries.

Estimated Discount To Fair Value: 28.3%

Fomento Económico Mexicano is trading at MX$191.66, significantly below its estimated fair value of MX$267.28, indicating a potential undervaluation based on discounted cash flow analysis. Despite a modest net profit margin decline from 4.8% to 1.7%, the company reported increased sales and net income for 2024, with earnings expected to grow significantly over the next three years at an annual rate of 21%, outpacing market averages.

BMV:FEMSA UBD Discounted Cash Flow as at Feb 2025

Wuhan Keqian BiologyLtd (SHSE:688526)

Overview: Wuhan Keqian Biology Co., Ltd is engaged in the research, development, production, and sales of veterinary biological products as well as providing animal epidemic prevention technical services in China, with a market cap of CN¥6.66 billion.

Operations: Revenue Segments (in millions of CN¥):

Estimated Discount To Fair Value: 36.4%

Wuhan Keqian Biology Ltd. is trading at CN¥14.23, well below its estimated fair value of CN¥22.38, highlighting a potential undervaluation based on discounted cash flow analysis. Despite a decline in sales and net income for 2024, earnings are projected to grow at an annual rate of 20.99% over the next three years, with revenue growth expected to surpass market averages significantly. However, the company has an unstable dividend track record and low forecasted return on equity of 11.6%.

SHSE:688526 Discounted Cash Flow as at Feb 2025

Aozora Bank (TSE:8304)

Overview: Aozora Bank, Ltd. operates as a provider of diverse banking products and services both in Japan and internationally, with a market capitalization of ¥310.25 billion.

Operations: The company's revenue segments include the Customer Relations Group with ¥8.48 billion, the Structured Finance Group with ¥38.85 billion, and the International Business Group with ¥15.69 billion.

Estimated Discount To Fair Value: 28.4%

Aozora Bank is trading at ¥2247.5, significantly below its estimated fair value of ¥3138.87, suggesting it may be undervalued based on discounted cash flow analysis. Despite a high level of bad loans (2.1%) and low forecasted return on equity (6.2%), earnings are projected to grow 56.42% annually over the next three years, outpacing market averages, though recent shareholder dilution and unsustainable dividend coverage remain concerns.

TSE:8304 Discounted Cash Flow as at Feb 2025

Turning Ideas Into Actions

Want To Explore Some Alternatives?

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

New: Manage All Your Stock Portfolios in One Place

We've created the ultimate portfolio companion for stock investors, and it's free.

• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks

Try a Demo Portfolio for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com